SBRT With S1 Combined With Endostar in the Treatment of Lung Cancer

Summary

Human recombinant endostatin preclinical studies have shown that the drug can inhibit endothelial cell proliferation, angiogenesis and tumor growth, still can directly induce lung cancer cell apoptosis, multiple clinical studies in human recombinant endostatin combined with chemotherapy treatment showed good antitumor efficacy and good safety.S1 is an oral fluorouracil derivative and an improved preparation of the antitumor drug tegafur.Multiple clinical studies have reported that S1 alone or S1 combined with chemotherapy is effective in Non small cell lung cancer(NSCLC).Unfortunately, none of the prospective clinical studies to date have systematically validated the safety and efficacy of antiangiogenic drugs combined with chemotherapy in patients with advanced pulmonary SCC.The investigators expect that endu combined with S1 will increase the efficacy of advanced lung squamous cell carcinoma.The purpose of this study was to evaluate the objective remission rate and safety of entu combined with oral S1 in the treatment of advanced lung squamous cell carcinoma.

Conditions

• Radiotherapy Side Effect

Interventions

DRUG

Endostar

Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.

Sponsors & Collaborators

• Mianyang Central Hospital

  collaborator OTHER

• Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  collaborator OTHER

• Peking University Cancer Hospital & Institute

  collaborator OTHER

• Peking University International Hospital

  collaborator OTHER

• China-Japan Friendship Hospital

  collaborator OTHER

• Beijing 302 Hospital

  collaborator OTHER

• Second Hospital of Shanxi Medical University

  collaborator OTHER

• Qingdao Hiser Medical Group

  collaborator OTHER

• Guangxi Ruikang Hospital

  collaborator OTHER

• Panjin Liaohe Oilfield Gem Flower Hospital

  collaborator OTHER

• Tang-Du Hospital

  collaborator OTHER

• Third Affiliated Hospital of Guizhou Medical University

  collaborator UNKNOWN

• Liuzhou Workers' Hospital

  collaborator OTHER_GOV

• The Affiliated Hospital of Xuzhou Medical University

  collaborator OTHER

• Dalian municipal central hospital affiliated of dalian medical university

  collaborator UNKNOWN

• Peking University Third Hospital

  lead OTHER

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2020-04-01

Primary Completion

2022-01-30

Completion

2023-01-30

Countries

• China

Study Locations